Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 14pembrolizumab 8Radiotherapy 7Nivolumab 7Radiotherapy, Intensity-Modulated 5Cetuximab 5Carboplatin 5Fluorouracil 4durvalumab 3Radiosurgery 3Magnetic Resonance Spectroscopy 3Docetaxel 3fluoromisonidazole 2epacadostat 2Standard of Care 2Specimen Handling 2Photochemotherapy 2Paclitaxel 2Drug Therapy 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Capecitabine 2C188-9 compound 2zimberelimab 1yeast-CEA vaccine 1vandetanib 1temoporfin 1talazoparib 1ruxolitinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Squamous Cell Carcinoma of Head and Neck × elgemtumab × Clear all
NCT02143622 2016-04-21

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

Novartis

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡